Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Molecular Partners Ag ADR (MOLN)

Molecular Partners Ag ADR (MOLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 213,185
  • Shares Outstanding, K 40,337
  • Annual Sales, $ 7,840 K
  • Annual Income, $ -69,040 K
  • EBIT $ -71 M
  • EBITDA $ -69 M
  • 60-Month Beta 0.98
  • Price/Sales 27.90
  • Price/Cash Flow N/A
  • Price/Book 1.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.45
  • Number of Estimates 1
  • High Estimate -0.45
  • Low Estimate -0.45
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +33.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.11 +3.43%
on 11/15/24
6.90 -23.40%
on 10/25/24
-1.28 (-19.56%)
since 10/22/24
3-Month
4.37 +20.94%
on 10/02/24
7.60 -30.46%
on 10/22/24
-1.41 (-21.12%)
since 08/22/24
52-Week
3.32 +59.19%
on 04/19/24
12.70 -58.39%
on 06/20/24
+0.95 (+21.78%)
since 11/17/23

Most Recent Stories

More News
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

MOLN : 5.29 (-2.49%)
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

MOLN : 5.29 (-2.49%)
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

MOLN : 5.29 (-2.49%)
Molecular Partners Announces Pricing of $20 Million Underwritten Offering

MOLN : 5.29 (-2.49%)
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

MOLN : 5.29 (-2.49%)
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

MOLN : 5.29 (-2.49%)
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

MOLN : 5.29 (-2.49%)
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy

Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy

AMAM : 28.00 (+0.07%)
MOLN : 5.29 (-2.49%)
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Incyte (NASDAQ:INCY) today announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development...

INCY : 71.72 (+1.89%)
MOLN : 5.29 (-2.49%)
PCVX : 88.54 (+0.17%)
AURA : 8.95 (-0.89%)
CNTA : 17.04 (-6.32%)
Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Molecular Partners AG (MOLN) Investors of Class Action and Last Few Hours to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Molecular Partners AG (“Molecular Partners” or the “Company”) (NASDAQ:...

MOLN : 5.29 (-2.49%)

Business Summary

Molecular Partners AG is a clinical-stage biotech company. It involved in developing a new class of custom-built protein drugs known as DARPin(R) therapeutics. Molecular Partners AG is based in SWITZERLAND.

See More

Key Turning Points

3rd Resistance Point 5.29
2nd Resistance Point 5.29
1st Resistance Point 5.29
Last Price 5.29
1st Support Level 5.29
2nd Support Level 5.29
3rd Support Level 5.29

See More

52-Week High 12.70
Fibonacci 61.8% 9.12
Fibonacci 50% 8.01
Fibonacci 38.2% 6.90
Last Price 5.29
52-Week Low 3.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar